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Chromosomal translocation t(8;21)(q22;q22) which leads to thegeneration of oncogenic RUNX1-RUNX1T1 (AML1-ETO) fusionis observed in approximately 10% of acute myelogenous
leukemia (AML). To identify somatic mutations that co-operate with
t(8;21)-driven leukemia, we performed whole and targeted exome
sequencing of an Asian cohort at diagnosis and relapse. We identified
high frequency of truncating alterations in ASXL2 along with recurrent
mutations of KIT, TET2, MGA, FLT3, and DHX15 in this subtype of
AML. To investigate in depth the role of ASXL2 in normal
hematopoiesis, we utilized a mouse model of ASXL2 deficiency. Loss of
ASXL2 caused progressive hematopoietic defects characterized by
myeloid hyperplasia, splenomegaly, extramedullary hematopoiesis, and
poor reconstitution ability in transplantation models. Parallel analyses of
young and >1-year old Asxl2-deficient mice revealed age-dependent per-
turbations affecting, not only myeloid and erythroid differentiation, but
also maturation of lymphoid cells. Overall, these findings establish a crit-
ical role for ASXL2 in maintaining steady state hematopoiesis, and pro-
vide insights into how its loss primes the expansion of myeloid cells.
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ABSTRACT
Introduction
Chromosomal translocation t(8;21) (q22;q22) is a frequent cytogenetic abnormal-
ity observed in approximately 10% of acute myelogenous leukemia (AML). This
rearrangement involves RUNX1 gene on chromosome 21 and RUNX1T1 gene on
chromosome 8 and results in generation of oncogenic RUNX1-RUNX1T1 fusion
protein (also known as AML1-ETO).1 However, expression of RUNX1-RUNX1T1
alone, either as a transgene or using viral transduction in hematopoietic cells, is
insufficient to cause leukemia in mice.2-4 Loss of sex chromosome and other chro-
mosomal aberrations, as well as recurrent somatic mutations of KIT, FLT3, NRAS
and KRAS, are associated with t(8;21) AML.2,4 Recent high-throughput sequencing
approach has identified additional mutagenic events
involving ASXL2, ASXL1 and DHX15 genes in t(8;21)
AML.5-10 Several secondary genetic events that co-operate
with RUNX1-RUNX1T1 fusion in inducing leukemia have
been demonstrated using mouse models.2-4,11 
ASXL1, ASXL2 and ASXL3 are human homologs of
Drosophila Asx (Additional sex combs) and function as
epigenetic regulators through recruitment of Polycomb
group repressor complexes (PRC) and Trithorax group
activator complexes.12,13 ASXL proteins can interact with
BAP1, NCOA1, EZH2, WTIP and nuclear receptors, which
suggests diverse functions of ASXL family members in
epigenetic and transcriptional regulation.12,13 Somatic
mutations of ASXL1 occur in a range of hematologic dis-
orders,14-20  and its deletion in mouse hematopoietic cells
results in multilineage cytopenias and dysplasia, which
are associated with global reduction of H3K27 trimethyla-
tion.21 In contrast, somatic mutations of ASXL2 are
observed exclusively in t(8;21) AML,5,8 while mutations of
ASXL3 are not reported in hematologic malignancies.13
Silencing of ASXL2 is partially embryonic lethal depend-
ing on the genetic background, and leads to congenital
heart defects. Surviving homozygous Asxl2 mutant mice
are smaller than wild-type littermates, demonstrate skele-
tal homeotic transformations consistent with disruption
of Polycomb/Trithorax complex functions, develop car-
diac dysfunction, and exhibit decreased bone mineral den-
sity.22-26 More recently, its role in normal hematopoietic
development and leukemic development has been investi-
gated.27,28 
In the present study, we used exome sequencing to
identify somatic mutations co-operating with RUNX1-
RUNX1T1 rearrangement in AML. Frequent truncating
mutations of ASXL2 were identified in our t(8;21) AML
cohort. Using an Asxl2-deficient mouse model, we aimed
to clarify the function of ASXL2 in hematopoiesis. We
demonstrate that ASXL2 is crucial to maintain hematopoi-
etic stem cell (HSC) number and function. Loss of ASXL2
leads to myeloproliferation and extramedullary
hematopoiesis, as well as to progressive defects in multi-
lineage differentiation. These results establish ASXL2 as a
key component of the epigenetic machinery involved in
maintaining hematopoietic development.  
Methods
Acute myelogenous leukemia samples 
t(8;21) AML was diagnosed by karyotypic analysis and/or
reverse transcriptase PCR assay for the detection of fusion tran-
script of RUNX1-RUNX1T1. Samples were collected with
informed consent at diagnosis, during complete remission, and at
time of frank relapse in accordance with the Declaration of
Helsinki. Bone marrow (BM) mononuclear cells were obtained by
Ficoll-Hypaque density gradient centrifugation (1.077 g/mL;
Amersham Pharmacia, Sweden). The study was approved by the
institutional review boards of the respective institutes. 
Exome sequencing and somatic variant discovery 
DNA was sheared using a Covaris instrument and assessed on
a 2100 Bioanalyzer. Library preparation and exome sequencing
were performed as described previously.29 For whole exome
sequencing, DNA were captured using SureSelect Human All
Exon 50Mb kit (Agilent), according to the manufacturer’s instruc-
tions. For targeted capture library, Agilent’s SureSelect XT2 Target
Enrichment System for Illumina Multiplexed Sequencing was
used. RNA baits were designed to capture exons of 530 genes
(Online Supplementary Table S1) and libraries were sequenced on
HiSeq 2000 (Illumina). 
100 bp paired-end reads were aligned to human reference
genome (reference build: hg19) using bwa-mem aligner with
default parameters. PCR duplicate reads were marked with sam-
blaster.30 Resulting BAM files were further processed according to
GTAK best practices including INDEL re-alignment and base qual-
ity recalibration (https://software.broadinstitute.org/gatk/best-prac-
tices/bp_3step.php?case=GermShortWGS). Somatic variants were
detected using Varscan2 somatic command.31 Raw variants were
processed with processSomatic command with the P-value set to
0.05 to obtain high confident variants. Variants were further
processed using fpFilter per script to remove potential false posi-
tives (https://github.com/ckandoth/variant-filter). Resulting variants
were annotated using Variant Effect Predictor and filtered against
germline variants in both dbSNP and ExAC, while keeping delete-
rious and clinically significant variants.32 For samples without
germline controls, variants were called using MuTect using a panel
of normal derived from in-house cohort of AML remission sam-
ples, as described previously.29,33 Oncoplots were drawn using
maftools Bioconductor package.34 All the somatic mutations for
whole exome sequencing and about 90% mutations reported for
targeted exome sequencing were validated using PCR amplifica-
tion and Sanger sequencing. 
Mice
Mice with Asxl2 gene-trap allele [referred to as knockout (KO)
allele in this study] have been described previously.24 Asxl2 het-
erozygous KO mice were maintained on C57BL/6J (B6) and 129Sv
(129) genetic backgrounds. Asxl2 homozygous null mice [and cor-
responding wild-type (WT) controls] used in all experiments were
B6 x 129 F1 obtained by crossing Asxl2 heterozygous B6 and 129
mice. Mouse colonies were housed and maintained at the animal
facility of Comparative Medicine Centre, National University of
Singapore (NUS). All mice experiments were approved by
Institutional Animal Care and Use Committee, NUS, Singapore.  
Flow cytometry
Cells were incubated with fluorochrome-conjugated antibodies
for 30 min on ice, washed and resuspended in SYTOX Blue Dead
Cell Stain (ThermoFisher Scientific) before acquisition on FACS
LSR II flow cytometer (BD Biosciences). Sorting of cells was per-
formed on FACSAria cell sorter (BD Biosciences) and data were
analyzed using FACSDIVA software (BD Biosciences). See Online
Supplementary Table S2 for the list of antibodies used for flow cyto-
metric staining.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 7
software.
Accession numbers
The accession numbers for the sequencing data reported in this
study are SRP122878 (exome sequencing) and GSE106798 (RNA
sequencing).
Results
Mutational profile of RUNX1-RUNX1T1 AML
We performed whole-exome sequencing of 10 paired
samples of newly-diagnosed and relapsed AML with
RUNX1-RUNX1T1 rearrangement from an Asian cohort,
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along with matched germline (complete remission) DNA
(Online Supplementary Table S3). We achieved a mean
depth of 100x (range 64-271x);  an average 68% of
nucleotides were covered by at least 20 reads (Online
Supplementary Figure S1). We identified 55 somatic muta-
tions (in 52 genes) in newly-diagnosed cases and 76 muta-
tions (in 69 genes) at relapse, which included recurrent
mutations in KIT, TET2, DHX15 and MGA (Online
Supplementary Table S4). We assessed the stability of muta-
tions in diagnosis and relapse samples analyzed using
whole exome sequencing. Overall, the disease evolution
followed the pattern reported previously for AML,35 as the
founding clone or a subclone at diagnosis survived the
therapy, gained additional mutations, and expanded at
relapse (Online Supplementary Figure S2). Interestingly, all
four mutations of TET2 (in 3 cases) were acquired at
relapse (Online Supplementary Table S4).
Further to uncovering the repertoire of co-operating
mutations in t(8;21) AML, we analyzed mutational status
of 530 genes (Online Supplementary Table S1) in 76 newly-
diagnosed and 19 relapse t(8;21) AML cases using target-
ed-exome sequencing (Online Supplementary Table S3). In
this cohort, the mean sequencing coverage across targeted
bases was 96x (range 76-319x), with 70% of bases covered
greater than 20x (Online Supplementary Figure S1).
Overall, we observed that the mutations of KIT were
most frequent at both diagnosis and relapse in our cohort,
along with recurring alterations in ASXL2, MGA, DHX15,
TET2 and FLT3 genes (Figure 1, Online Supplementary Table
S5 andOnline Supplementary Figure S3). Somatic mutations
of ASXL2 were detected in 20% of newly-diagnosed (17
of 86) and 10% of relapsed (3 of 29) cases while ASXL1
was mutated at a much lower frequency (2% of newly-
diagnosed cases and 7% of relapsed cases) (Figure 1,
Online Supplementary Table S5 and Online Supplementary
Figure S3). Mutations of DHX15, a RNA helicase, occurred
exclusively at Arg222 residue in 7 cases. MGA and TET2
genes predominantly harbored nonsense and frameshift
mutations spread throughout the transcript (Figure 1,
Online Supplementary Figure S3 and Online Supplementary
Table S5). 
ASXL2 was the second most frequently mutated gene,
and interestingly, all alterations were truncating mutations
located in exons 11 and 12 (Figure 1 and Online
Supplementary Figure S3). Unlike alterations of ASXL1,
which are recurrent in several hematologic diseases,
recent reports5,8,9 have highlighted the incidence of ASXL2
mutations specifically in the t(8;21) subtype of AML. In
this study, we aimed to investigate the consequences of
deficiency of ASXL2 on hematopoietic development using
a mouse model.
Impaired hematopoiesis in Asxl2-deficient mice
Our RT-PCR analysis showed that Asxl2 is expressed in a
broad range of murine hematopoietic cell types (Online
Supplementary Figure S4A). To investigate the physiological
role of ASXL2 in steady-state hematopoiesis, we used gene-
trap mice (referred to as Asxl2KO mice) described previous-
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Figure 1. Mutational landscape of t(8;21) acute myelogenous leukemia (AML). Matrix displays individual somatic mutations detected in diagnosis and relapse AML
with RUNX1-RUNX1T1 fusion.  Mutational frequencies are illustrated on the left  and bar graphs on the right  depict absolute number and type of mutations. The
annotation bars at the bottom display patient information including the cytogenetic aberrations detected in karyotype analysis. NA: information not available.
ly.24 As reported,24 Asxl2 KO mice had a significantly shorter
life span compared with the WT mice (Online Supplementary
Figure S4B). We observed a significant reduction in Asxl2
transcript and protein levels in the BM, spleen and thymus
of Asxl2 KO mice compared to WT mice (Online
Supplementary Figure S5A-F), whereas the expression of
Asxl1 was not affected (Online Supplementary Figure S5G-I).
We cultured the BM cells from WT and KO mice for two
weeks in myeloid differentiation-promoting conditions and
observed an increase in the proportion of CD11b+ cells with
a concomitant decrease in Lin–Kit+ cells in the cultures from
Asxl2-deficient BM, suggesting altered myeloid differentia-
tion (Online Supplementary Figure S6A and B). Moreover, in
re-plating assays, we observed a sustained ability of Asxl2
KO BM cells to generate myeloid colonies compared with
WT cells (Online Supplementary Figure S6C).
To gain initial insights into the effect of ASXL2 deficien-
cy on hematopoiesis in vivo, we periodically analyzed the
peripheral blood (PB) from Asxl2 KO and WT mice begin-
ning at eight  weeks of age. We observed an age-depen-
dent increase in white leukocyte count in the PB of Asxl2-
deficient mice, while the numbers were unchanged in the
WT mice (Figure 2A). This was associated with reduced
red blood cell (RBC) counts and hemoglobin in peripheral
blood of Asxl2 KO mice with increasing age (Online
Supplementary Figure S7). This observation suggested pro-
gressive defects in the hematopoietic compartment in
Asxl2 KO mice, and therefore we investigated systemati-
cally hematopoietic development in >1-year old mice.
Flow cytometric analysis of blood leukocytes from these
mice showed a higher proportion of myeloid (CD11b+)
and a reduced proportion of lymphoid (CD19+ and CD3+)
cells in KO mice (Figure 2B and Online Supplementary Figure
S8A). Old Asxl2 KO mice exhibited extensive
splenomegaly (Figure 2C and D) which was associated
with marked myeloproliferation evident by increased fre-
Progressive hematopoietic defects in ASXL2 KO mice
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Figure 2 Myeloproliferation and extramedullary hematopoiesis in Asxl2-deficient mice. (A) White blood cell counts in peripheral blood of 8-10 week old wild-type
(WT) and Asxl2-deficient mice. Whiskers extend from the minimum to the maximum values. (B) Proportion of B cells (CD19+), T cells (CD3+), and myeloid cells
(CD11b+) in the peripheral blood of >1-year old WT and Asxl2 knockout (KO) mice determined using flow cytometry (B and T cells, n=3; myeloid cells, n=11). (C)
Representative photograph of spleens isolated from young (11-week old) and old (>1-year old) WT and Asxl2 KO mice. (D) Total leukocyte counts in spleens from
>1-year old mice. (E and F)  Frequencies (E) and absolute numbers (F) of lymphoid and myeloid cells in spleens of old WT and KO mice. Flow-cytometric analysis on
splenocytes was similar to (B) (n=12-13). (G) Frequency of LSK cells in spleen and peripheral blood of old WT and KO mice. (H) Proportion of erythroid progenitors
detected in flow cytometric analysis (staining with CD71 and TER119 antibodies) of spleens from old WT and KO mice (n=10). Bars represent mean±Standard Error
of Mean. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns: not significant.
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Figure 3. ASXL2 deficiency perturbs frequency and function of hematopoietic stem cells (HSCs.) (A) Representative photograph of tibias and femurs, respectively,
from >1-year old wild-type (WT) and Asxl2 knockout (KO) mice. (B) Bone marrow (BM) cellularity (two femurs and two tibias) in old WT and Asxl2 KO mice. (C)
Proportion of LSK cells in the BM of old mice (n=14). (D) Frequency of BrdU+ LSK cells in the BM of 10-20-weeks old WT and Asxl2 deficient mice (n=5). (E)
Proportions of CMP, GMP and MEP in the BM of >1-year old WT and KO mice (n=12). (F) Frequency of erythroid precursors (proE: CD71+TER119lo, EryA:
CD71+TER119+FSChi, EryB: CD71+TER119+FSClo and EryC: CD71–TER119+FSClo) in BM of >1-year old WT and Asxl2 KO mice (n=8). (G-J) Competitive repopulation
assay: 4000 (black circles) or 2000 (gray circles) LSK cells were injected in recipient mice and proportion of donor-derived cells (CD45.2+) in peripheral blood was
determined at 4, 8, 12 and 16 weeks post transplantation. Ability of WT and Asxl2 KO LSK cells to reconstitute B cells (CD19+) (G), T cells (CD3+) (H), granulocytes
(CD11b+Gr1+), (I)  and monocytes (CD11b+Gr1–F4/80+) (J) was analyzed using flow cytometry. Bars represent mean±Standard Error of Mean. *P<0.05, ***P<0.001,
****P<0.0001, ns: not significant.
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quency of CD11b+ cells and myeloperoxidase-positive
cells (Figure 2E and Online Supplementary Figure S8B and
C). The absolute numbers of CD11b+ myeloid cells were
significantly increased (20-fold) while the number of lym-
phoid cells were 2-fold higher in the spleens of KO mice
compared with the WT mice (Figure 2F). Histological
examination of spleens demonstrated loss of normal archi-
tecture in KO mice compared with the WT mice (data not
shown). Moreover, extramedullary hematopoiesis in the
KO spleens was evident by an elevated proportion and
numbers of total Lin–Kit+ and Lin–Kit+Sca1+ (LSK) cells
(Figure 2G and Online Supplementary Figure S9A-D) as well
as significantly higher frequency of erythroid progenitors
(populations proE, EryA and EryB) (Figure 2H and Online
Supplementary Figure S9E). We also detected markedly
increased frequency of stem/progenitor cells in the periph-
eral blood of old KO mice (Figure 2G and Online
Supplementary Figure S9F). 
Parallel analyses of spleens from young KO mice (8-14
weeks old) revealed modestly increased spleen size with a
trend towards elevated proportion and number of LSK
cells (Online Supplementary Figure S10A-C). A propensity
for increased frequencies of myeloid cells (CD11b+) and
erythroid progenitors was also noted in the spleens of
young KO mice (Online Supplementary Figure S10D and E).
This indicates an onset of extramedullary hematopoiesis
in young mice, which manifests by marked myeloid and
erythroid cell expansion as the mice grow older. 
ASXL2 deficiency results in defective differentiation
and function of hematopoietic stem cells
ASXL2 deficiency resulted in paler bones and decreased
marrow cellularity in old mice (Figure 3A and B). Notably,
BM of old Asxl2 KO mice had higher frequency and
absolute number of LSK cells compared with the WT mice
(Figure 3C and Online Supplementary Figure S11A and B).
The proportion of LT-HSCs (CD34–Flt3–LSK), ST-HSCs
(CD34+Flt3–LSK) and MPPs (CD34+Flt3+LSK) within the
LSK compartment was largely unaltered (Online
Supplementary Figure S11C), albeit an overall increase in
the absolute number of these subpopulations occurred in
the old KO mice (Online Supplementary Figure S11D and E).
We also observed reduced BM cellularity in young KO
mice; and although the proportion of LSK cells was not
significantly altered, the frequency and absolute numbers
of LT-HSCs were significantly higher, suggesting early
defects in maintaining HSC frequency (Online
Supplementary Figure S11F-J). In vivo BrdU incorporation
assay uncovered a significantly higher frequency of BrdU+
LSK cells in the BM of Asxl2 KO mice, indicating increased
cycling of  stem/progenitor cells lacking ASXL2 (Figure
3D). These results illustrate that ASXL2 is required for
maintaining the number and self-renewal of HSCs during
steady-state hematopoiesis. 
Flow cytometric analyses also demonstrated decreased
proportion and number of common myeloid precursors
(CMP; Lin–Kit+Sca1–CD34+FcgRII/IIIlo) and granulocyte
monocyte precursors (GMP; Lin–Kit+Sca1–
CD34+FcgRII/IIIhi) in >1-year old Asxl2 KO mice (Figure 3E
and Online Supplementary Figure S12A and B). Furthermore,
a marked reduction in the frequencies of erythroid precur-
sors was noted in the old KO mice (Figure 3F and Online
Supplementary Figure S12C), indicating impaired erythro-
poiesis.  Reduction in erythroid precursors as well as CMP
and GMP populations was also apparent in the BM of the
young KO mice, signifying an early inception of defects in
erythroid and myeloid differentiation because of ASXL2
deficiency (Online Supplementary Figure S12D-F).
Further, multi-lineage reconstitution ability of 
Asxl2-deficient HSCs was assessed in a competitive repop-
Progressive hematopoietic defects in ASXL2 KO mice
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Figure 4. ASXL2 is essential for normal thymocyte maturation. (A) Thymocyte count in >1-year old wild-type (WT) and Asxl2 knockout (KO) mice. (B) Representative
FACS plots depict the proportion of DN (CD4–CD8–), DP (CD4+CD8+), CD4+ single positive (SP) and CD8+ SP cells in the thymus of old WT and Asxl2 KO mice. (C)
Frequencies of DP, DN, CD4+ SP and CD8+ SP populations in old WT (n=17) and Asxl2 KO (n=18) mice. (D) FACS plots show representative flow cytometric staining
for surface expression of CD44 and CD25 within the DN population in the thymus of old mice. (E) Proportions of DN1 (CD44+CD25– DN), DN2 (CD44+CD25+ DN),
DN3 (CD44–CD25+ DN) and DN4 (CD44–CD25– DN) sub-populations within the DN compartment of thymus of old WT and KO mice. (F and G) Frequencies of myeloid
cells (CD11b+) (F) and B cells (CD19+) (G) in the thymus of >1-year old WT and KO mice (n=5-7). Data are represented as mean±Standard Error of Mean.
***P<0.001, ****P<0.0001.
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ulation assay. ASXL2 deficiency resulted in poor reconsti-
tution of lymphoid lineage (both B and T cells) compared
with the WT cells (Figure 3G and H). The reconstitution of
granulocytes was also impaired in mice transplanted with
Asxl2-deficient LSK cells (Figure 3I), while the proportion
of donor-derived monocytes was similar to the recipients
transplanted with WT cells (Figure 3J). These repopulation
assays demonstrated that ASXL2 is essential for differen-
tiation into multiple hematopoietic lineages including the
lymphoid lineage, prompting us to investigate the devel-
opment of lymphoid lineage in the Asxl2 KO mice.
Impaired thymopoiesis in mice lacking ASXL2
A marked reduction of thymus size and cellularity was
a consistent feature in >1-year old Asxl2 KO mice com-
pared with the WT mice (Figure 4A). Flow cytometric
analyses revealed a striking reduction in CD4+CD8+ dou-
ble positive (DP) cells and a concomitant increase in the
proportion and number of CD4–CD8– double negative
(DN) cells in the thymi of Asxl2 KO mice (Figure 4B and C
and Online Supplementary Figure S13A). Within the DN
compartment, the proportion of DN1 (CD44+CD25–) sub-
population was unchanged, whereas a significant reduc-
tion was detected in the proportion of DN2
(CD44+CD25+) and DN3 (CD44–CD25+) subpopulations,
indicating a partial block in differentiation of earliest thy-
mocytes (Figure 4D and E). A large number of DN cells in
the thymi of KO mice consisted primarily of CD25– cells,
present in the DN1 and DN4 gates (Figure 4D and Online
Supplementary Figure S13B). Further characterization
showed that the vast majority of cells in the DN gate were
CD19+ (which contributed to 40% of total thymus-resid-
ing hematopoietic cells), and the frequency and number of
CD11b+ myeloid cells were also noticeably increased in
the thymus of KO mice compared with the WT mice
(Figure 4F and G and Online Supplementary Figure S13C-F). 
Young Asxl2 KO mice exhibited decreased thymus cel-
lularity, but displayed less pronounced effect on major
thymic compartments compared with the >1-year old
mice (Online Supplementary Figure S13G-I). These findings
illustrate that ASXL2 is essential for maintaining normal
thymopoiesis in mice and its deficiency leads to progres-
sive impairment in thymocyte maturation, which is man-
ifested by a partial block from the DN to the DP stage, and
an accumulation of myeloid and B cells in the thymus of
the old mice.
Defects in B-cell development in Asxl2 knockout mice
We also examined the consequences of ASXL2 deficien-
cy on B-cell development in the BM by examining the
expression of several surface antigens, which define the
advancing stages of B-cell maturation. While the young
Asxl2 KO mice showed largely conserved subsets during
B-cell lymphopoiesis, a notable decrease in the proportion
of mature B cells (CD43–IgM+B220hi) compared with the
WT mice was observed (Online Supplementary Figure S14).
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Figure 5. Impaired B-cell lymphopoiesis in Asxl2-deficient mice. (A and B) Proportion (A) and absolute number (B) of cells at different stages of B-cell development
in the bone marrow of >1-year old WT and Asxl2 KO mice (n=4-6). proB: CD43+B220+, preB: CD43–B220+IgM–, immature B (Imm. B): CD43–B220+IgM+, mature B
(Mat. B): CD43–B220hiIgM+, Fraction A (Fr. A): CD24–BP1– proB cells, Fraction B (Fr. B): CD24+BP1– proB cells, Fraction C (Fr. C): CD24+BP1+ proB cells. Data are rep-
resented as mean±Standard Error of Mean. *P<0.05, **P<0.01, ***P<0.001, ns: not significant.
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However, the BM of old KO mice showed a substantial
reduction in the frequencies and absolute number of proB
(CD43+B220+), preB (CD43–IgM–B220+), immature B
(CD43–IgM+B220+), and mature B cells (Figure 5A and B),
indicating an age-dependent paucity in B-cell develop-
ment. Further fractionation of proB cells using the scheme
proposed previously,36 revealed a lower proportion of
CD24–BP1– (Fraction A) and CD24+BP1– (Fraction B) proB
cells in the old Asxl2 KO mice (Figure 5A and B), demon-
strating a partial arrest of B-cell maturation.
Cell-intrinsic role of ASXL2 in hematopoiesis
To test the cell-autonomous function of ASXL2 in
hematopoietic development, we transplanted lethally irra-
diated mice with either WT or Asxl2 KO BM cells and ana-
lyzed the hematopoietic compartment one year later. We
observed that the recipient mice transplanted with Asxl2
KO BM cells tended to have higher WBC counts in periph-
eral blood (Figure 6A), similar to the age-dependent
increase in WBC observed in KO mice (Figure 2A). We
also noted decreased thymocyte cellularity and accumula-
tion of donor-derived DN cells in the thymi of mice trans-
planted with Asxl2 KO BM compared with those trans-
planted with WT BM (Figure 6B and C). Spleens of Asxl2
KO BM-recipients were enlarged and exhibited elevated
proportion of myeloid cells (Figure 6D and E). Moreover,
our analysis also indicated a higher proportion of ery-
throid precursors in spleens of mice reconstituted with
Asxl2 KO BM cells compared with the WT cells (Figure
6F), similar to the phenotype observed in old Asxl2 KO
mice. Overall, the recipient mice recapitulated hematopoi-
etic features of old Asxl2 KO mice, suggesting a
hematopoietic cell-intrinsic function of ASXL2.
Identification of altered gene expression in 
ASXL2-deficient hematopoietic stem cells
To determine the molecular basis of the defects
observed in Asxl2 KO HSCs, we performed global gene
expression profiling (RNA-Sequencing) of sorted LSK cells
from old and young WT and Asxl2 KO mice. Comparison
of transcriptomic profiles of LSK cells from old WT and
Asxl2 KO identified more than 2500 genes differentially
expressed (983 genes up-regulated and 1653 genes down-
regulated in the KO cells; FDR<0.1) (Online Supplementary
Table S6), including those involved in myeloid differentia-
tion such as Csf1, Gfi1b, Gata2, Hoxa9, Hoxa5, Mpl, Cdk6,
Ccr1 and Ets1 (Online Supplementary Figure S15A). 
Asxl2-deficient LSK cells from old mice exhibited more
pronounced changes in gene expression compared with
the young mice (Figure 7A and B and Online Supplementary
Figure S15B). However, a significant overlap of genes com-
monly up-regulated and down-regulated in the KO LSK
cells was noted within the two age groups (Figure 7C and
Online Supplementary Table S6). Interestingly, GSEA analy-
sis revealed that the expression of RUNX1-RUNX1T1 tar-
gets37 inversely correlated in the KO cells (Figure 7D and
Online Supplementary Figure S15C). Also, genes down-reg-
ulated in immature BM progenitors upon silencing of
CBFA2T3 (also called ETO2)38 were also suppressed in the
LSK cells from both old and young Asxl2 KO mice (Figure
7E and Online Supplementary Figure S15D). CBFA2T3 is
involved in the translocation t(16;21)(q24;q22) with
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Figure 6. Cell-intrinsic effects of Asxl2 deficiency on lymphoid and myeloid lineages. Lethally irradiated mice transplanted with either wild-type (WT) or Asxl2 knock-
out (KO) bone marrow  (BM) cells were analyzed after one year. (A) Number of white blood cells (WBCs) in the peripheral blood of recipient mice. (B) Number of thy-
mocytes in recipient mice. (C) Proportion of donor-derived (CD45.2+) DN, DP, CD4+SP and CD8+SP cells in thymi of recipient mice. (D) Spleen cellularity. (E)
Percentages of CD45.2+ B, T and myeloid cells in the spleen of mice transplanted with either WT or KO cells. (F) Frequencies of erythroid precursors in spleens of
recipient mice. Bars represent mean±Standard Error of Mean. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
A B C
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RUNX1 in AML, a disease with phenotypic and transcrip-
tional profile reminiscent of t(8;21) AML.39,40
Discussion
This study, along with recent reports,5-10 provides a com-
prehensive landscape of the mutational spectrum of
t(8;21) AML, which is distinctive from other subtypes of
AML and characterized by high frequency of alterations of
KIT, ASXL2, DHX15 and MGA genes; and rare mutations
of other commonly altered genes in myeloid leukemia
(DNMT3A, RUNX1, IDH2, NPM1). Truncating mutations
of ASXL2 occurred in 20% of newly-diagnosed t(8;21)
AML cases, and were localized to exons 11 and 12, a pat-
tern highly reminiscent of the mutational profile for
ASXL1 in hematologic malignancies.41,42 However, unlike
ASXL1, which is altered in a diverse range of hematologic
diseases, mutations of ASXL2 are specific to the t(8;21)
AML subtype. We also noted that the mutational frequen-
cy of RAS pathway genes (NRAS and KRAS) and ZBTB7A
in our Asian cohort of t(8;21) AML were notably lower
V. Madan et al.
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Figure 7. Gene expression
changes in Asxl2-deficient LSK
cells. (A and B) Changes in tran-
script levels in LSK cells from >1-
year old (A) and young (8-12-
week old) (B) Asxl2 knockout
(KO) versus wild-type (WT) litter-
mates. For each age group and
genotype, cells from 2 mice were
analyzed. Genes significantly up-
regulated in KO cells are repre-
sented in red circles while down-
regulated genes are shown in
blue (FDR<0.1). (C) Venn dia-
grams show overlap of genes
either up-regulated or down-reg-
ulated in young and old Asxl2 KO
LSK cells compared with the WT
cells from young and old mice,
respectively.  (D and E) GSEA
comparing expression of genes
in LSK cells from >1-year old WT
and KO littermates for the select-
ed gene sets (FDR<0.1): genes
up-regulated in normal
hematopoietic progenitors by
RUNX1-RUNX1T1 fusion (D), and
genes down-regulated in
hematopoietic progenitors in
CBFA2T3 KO mice (E). NES: nor-
malized enrichment score.
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than previous reports from Western populations.5,7-9,40,43 We
obtained a mutational rate of 6% for NRAS and 2% for
KRAS compared to 13-26% for NRAS and 4-7% for KRAS
observed in previous studies.5,7-9,43 Similarly, ZBTB7A
mutations that are frequent  in  Caucasian t(8;21) AML (9-
23%)9,40,43 were observed in only 3% of our Asian patient
cohort. Although this might reflect a true difference
between genetic backgrounds, this requires further confir-
mation  in independent t(8;21) AML cohorts from differ-
ent genetic backgrounds. 
In this study, we focused on functional characterization
of Asxl2 in hematopoietic differentiation using a mouse
model of Asxl2 deficiency. Mice used in this study were
C57BL/6 x 129Sv F1 as the animals in either C57BL/6 or
129Sv background die perinatally,23 which precludes inves-
tigation of Asxl2 knockout on an inbred genetic back-
ground. Moreover, this mouse model exhibits constitutive
loss of Asxl2, which is distinct from the truncating somatic
mutations of ASXL2 observed in t(8;21) AML that may
possibly generate a C-terminal truncated protein. Despite
these limitations, our study strengthens the findings con-
cerning the key role of ASXL2 in hematopoiesis reported
in two recent studies.27,28 Furthermore, our study reports
several additional features of Asxl2 deficient mice, which
had not been described previously. While the significance
of ASXL2 in maintaining normal hematopoiesis is evi-
denced from these studies, we performed a parallel in-
depth analysis in young (8-14 weeks old) versus old (>1-
year old) mice, which helped establish the progressive
phenotype associated with Asxl2 deficiency, including
uncovering the crucial function of ASXL2 in development
of the lymphoid lineage. Age-dependent defects in
hematopoiesis in the knockout mice were characterized
by an increased proportion of LSK cells and reduced fre-
quencies of CMP and GMP cells in the BM of >1-year old
KO mice. Asxl2-deficient mice also exhibited a progressive
myeloproliferative phenotype, accompanied by increased
peripheral WBC counts, splenomegaly and
extramedullary hematopoiesis, indicating perturbed
hematopoiesis. In addition, erythroid maturation was
impaired in the old mice lacking ASXL2, signifying age-
dependent defects in erythroid development. Both previ-
ous studies showed that ASXL2 deficiency led to poor
reconstitution ability of HSCs in transplantation models,
consistent with our findings. We observed that Asxl2-defi-
cient LSK cells exhibited poor reconstitution ability of the
lymphoid lineage and flow cytometric analyses of >1-year
old mice demonstrated defects in both T-cell maturation
in the thymus and B-cell development in the BM of the old
KO mice. Apart from the intrinsic effect of ASXL2 on lym-
phoid differentiation, chronic overproduction of myeloid
cells and accompanying inflammatory signals in the mice
lacking ASXL2 may also negatively affect the lymphoid
output. These findings establish ASXL2 as an essential
component of hematopoietic development in mice. 
Gene expression analysis of sorted LSK cells from WT
and Asxl2 KO BM identified several key regulators of
hematopoiesis as downstream targets of ASXL2 in HSCs.
Prominently, GSEA analysis revealed that the expression
of genes regulated by RUNX1-RUNX1T1 correlated with
the expression of ASXL2, indicating ASXL2 is possibly
required for transcriptional activity of RUNX1-RUNX1T1.
An identical finding was described recently for Asxl2-defi-
cient LSK cells in an independent mouse model. Here the
authors also detected binding of ASXL2 to the genomic
loci occupied by RUNX1 and RUNX1-RUNX1T1,
although no direct interaction between ASXL2 and either
RUNX1 or RUNX1-RUNX1T1 was observed.27 Further
studies are needed to investigate whether ASXL2 acts as a
likely co-regulator of RUNX1-RUNX1T1 during leukemo-
genesis. GSEA also indicated a correlation between Asxl2
deficiency and the expression levels of reported targets of
BMI1 (a PRC1 member)44 and SUZ12 (a PRC2 member)45
(Online Supplementary Figure S15E and F), consistent with a
role for ASXL2 in transcriptional regulation mediated
through the PRC complexes.12
In summary, the current study identified frequent
ASXL2mutations in t(8;21) AML and characterized its role
in hematopoietic development in mice. This work demon-
strates that ASXL2 plays a critical role in multi-lineage dif-
ferentiation and highlights how its loss leads to progres-
sive hematopoietic defects and promotes myeloid expan-
sion, thereby advancing our understanding of epigenetic
machinery that regulates hematopoiesis.
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